Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B

Recruiting now · Phase 1

Conditions studied: HEPATITIS B CHRONIC

In brief

This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.

Key facts

Study ID

NCT06680232

Run by

Precision BioSciences, Inc.

People needed

45

Starts

2024-11-14

Expected to finish

2026-12-01

Last updated by the study team

2025-09-26

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Massachusetts General Hospital/Harvard University — Boston, Massachusetts, United States (enrolling)
• Queen Mary Hospital, The University of Hong Kong — Hong Kong, Hong Kong, Hong Kong (enrolling)
• ICS ARENSIA Exploratory Medicine SRL — Chisinau, Moldova (enrolling)
• New Zealand Clinical Research — Auckland, New Zealand (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.